These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10167344)

  • 1. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic foundations of cost-effectiveness analysis.
    Garber AM; Phelps CE
    J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.
    Meltzer D; Egleston B; Stoffel D; Dasbach E
    Med Care; 2000 Jun; 38(6):679-85. PubMed ID: 10843315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example.
    Hornberger JC; Best JH; Garrison LP
    Med Decis Making; 1997; 17(4):363-72. PubMed ID: 9343794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility and cost-benefit analyses: how did we get here and where are we going?
    Moayyedi P; Mason J
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):527-34. PubMed ID: 15167153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and health economics: where is the link?
    Jönsson B
    Scand J Gastroenterol Suppl; 1996; 221():33-6. PubMed ID: 9110396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.
    Meltzer D; Johannesson M
    Med Decis Making; 1999; 19(4):371-7. PubMed ID: 10520672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.
    Etzioni R; Ramsey SD; Berry K; Brown M
    Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A second opinion. Cost-utility analysis and varying preferences for health.
    Mooney G; Jan S
    Health Policy; 1997 Sep; 41(3):201-3; discussion 203-5. PubMed ID: 10170089
    [No Abstract]   [Full Text] [Related]  

  • 15. Theoretical issues in cost-effectiveness analysis.
    Weinstein MC; Manning WG
    J Health Econ; 1997 Feb; 16(1):121-8. PubMed ID: 10167343
    [No Abstract]   [Full Text] [Related]  

  • 16. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost, effectiveness, and cost-effectiveness.
    Diamond GA; Kaul S
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):49-54. PubMed ID: 20031812
    [No Abstract]   [Full Text] [Related]  

  • 18. Endogenous patient responses and the consistency principle in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Med Decis Making; 2012; 32(3):488-97. PubMed ID: 22101019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
    Manns B; Meltzer D; Taub K; Donaldson C
    Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis.
    Jiao B; Basu A
    Value Health; 2021 Jul; 24(7):957-965. PubMed ID: 34243839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.